Back

Mavacamten shows benefits in patients with symptomatic obstructive hypertrophic cardiomyopathy with latent obstruction: global evidence from COLLIGO-HCM

28 August 2026 (09:15 - 10:00)
Organised by: Logo
Congress Presentation Part of: Hypertrophic cardiomyopathy: artificial intelligence and risk prediction Hypertrophic Cardiomyopathy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Elizabeth Paratz

St. Vincent's Institute of Medical Research, Melbourne (Australia)

7 More presentations in this session

Presentation thumbnail
Distinct comorbidity and functional profiles in obstructive versus non-obstructive hypertrophic cardiomyopathy in the prospective TORCH registry
Doctor C. Reich (Heidelberg, DE)
Abstract Slides Video
Presentation thumbnail
Artificial intelligence–driven temporal clinical and ECG modeling for personalized sudden cardiac death risk prediction in hypertrophic cardiomyopathy
Doctor L. Ordine (Naples, IT)
Abstract Slides Video
Presentation thumbnail
Evaluation of the localization of coronary microvascular dysfunction in obstructive hypertrophic cardiomyopathy and the therapeutic effects of alcohol septal ablation
Doctor T. Terauchi (Tsukuba, JP)
Abstract Slides Video
Presentation thumbnail
Long-term prognostic value of left ventricular outflow tract gradient in hypertrophic cardiomyopathy
Mr E. Klaassen Barba (Rotterdam, NL)
Abstract Slides Video
Presentation thumbnail
Enhancing clinical care in obstructive hypertrophic cardiomyopathy: the use of artificial intelligence for echocardiographic follow-up during treatment with mavacamten.
Ms A. Van Hoogdalem (NL)
Abstract Slides Video

Access the full session

Session thumbnail
Hypertrophic cardiomyopathy: artificial intelligence and risk prediction

The Event

Event poster

ESC Congress 2026

28 August 2026 09:15 CET
You may be interested in
thumbnail
Congress Presentation
Consistent real world effectiveness of mavacamten across global regions in symptomatic obstructive hypertrophic cardiomyopathy: results from COLLIGO HCM
30 August 2026
thumbnail
Congress Presentation
Characteristics and long-term outcomes of asymptomatic patients with hypertrophic cardiomyopathy
30 August 2025
thumbnail
Congress Presentation
Effect of mavacamten on left atrial remodeling and function in obstructive hypertrophic cardiomyopathy. A real-world multicentric prospective study.
29 August 2026
thumbnail
Congress Presentation
Mavacamten use in a real-world cohort of obstructive hypertrophic cardiomyopathy patients: insights from the initial centre experience
18 May 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources